Abstract
Perioperative tumor growth acceleration is associated with inflammatory pathway activation. Non-steroidal anti-inflammatory drugs, particularly ketorolac, are a promising way to improve patient outcome.
Translated title of the contribution | A single intraoperative dose of original ketorolac to prevent cancer recurrence: Is that too simple? |
---|---|
Original language | French |
Pages (from-to) | 391-395 |
Number of pages | 5 |
Journal | Louvain Medical |
Volume | 133 |
Issue number | 6 |
Publication status | Published - Jun 2014 |
Keywords
- Ketorolac
- postoperative cancer recurrence
- Inflammation